Prediction of prognosis and clinical application of gene methylation score in urothelial cancers

尿路上皮癌基因甲基化评分的预后预测及临床应用

基本信息

  • 批准号:
    18591761
  • 负责人:
  • 金额:
    $ 2.51万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2006
  • 资助国家:
    日本
  • 起止时间:
    2006 至 2007
  • 项目状态:
    已结题

项目摘要

Purpose : Many genes responsible for the bladder cancer progression have been isolated recently. We have reported thathypermethylation of 2 tumor suppressor genes, pl6INK4a and p14ARF is involved in poor prognosis and tumor invasiveness in patients with bladder cancer. In the present study, we examined methylation status of collagen 1A2 gene promoter region in terms of prediction of patient prognosis.Materials and Methods : We examined methylation status of collagen 1A2 gene in the presence and absence of demethylation agent, 5 aza-cytizine in human BOY cultured bladder cancer cells. We examined the frequency of methylation of collagen 1A2 gene in 97 clinical specimens from radical cystectomy and TURBT. Furthermore, we transfected collagen 1A2 gene into human bladder cancer cells and examined cell migration ability and growth rate in both transfectants and control cells.Results : Gene expression of collagen 1A2 gene was increased by 5 aza-cytizine treatment. Collagen 1A2 gene expression in bladder tumors was significantly lower than that in normal bladder tissues. Methylation scores in the bladder tumors are significantly higher that those in normal bladder tissues. Cell migration and growth rate in collagen 1A2 gene transfectants are significantly decreased compared to those in control cells.Conclusions : Collagen 1A2 gene expression is suppressed by the promoter methylation in human bladder cancers. These results suggest that collagen 1A2 gene plays a role in tumor suppressor in human bladder cancer.
目的:近年来,许多与膀胱癌进展有关的基因被分离出来。我们已经报道了两个抑癌基因p16INK4a和p14ARF的甲基化与膀胱癌患者的不良预后和肿瘤侵袭性有关。在本研究中,我们研究了胶原1A2基因启动子区的甲基化状态在预测患者预后方面。材料和方法:我们研究了胶原1A2基因甲基化状态的存在和不存在的去甲基化剂,5氮胞苷在人BOY培养的膀胱癌细胞。我们检测了97例根治性膀胱癌和TURBT的临床标本中胶原1A2基因甲基化的频率。结果:5氮胞苷处理后,1A2胶原基因表达增加,细胞迁移能力增强,细胞生长速度加快。膀胱肿瘤组织中胶原1A2基因表达明显低于正常膀胱组织。膀胱肿瘤组织的甲基化评分明显高于正常膀胱组织。结论:1A2基因启动子区甲基化抑制了人膀胱癌组织中1A2基因的表达。提示胶原1A2基因在膀胱癌中起抑癌作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Roles of collagen 1A2 gene methylation in bladder cancer
胶原1A2基因甲基化在膀胱癌中的作用
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Mori;K;et. al.
  • 通讯作者:
    et. al.
膀胱癌進展における遺伝子メチル化の役割
基因甲基化在膀胱癌进展中的作用
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    榎田 英樹;ほか
  • 通讯作者:
    ほか
膀胱癌におけるCOL1A2遺伝子プロモーター領域のメチル化の検討
膀胱癌COL1A2基因启动子区甲基化检测
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kawakami;K;et. al.;吉田 正貴;森 勝久・他
  • 通讯作者:
    森 勝久・他
Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling.
  • DOI:
    10.3892/or.16.3.521
  • 发表时间:
    2006-09
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Kazumori Kawakami;H. Enokida;T. Tachiwada;T. Gotanda;Kengo Tsuneyoshi;H. Kubo;K. Nishiyama;M. Takiguchi-M.
  • 通讯作者:
    Kazumori Kawakami;H. Enokida;T. Tachiwada;T. Gotanda;Kengo Tsuneyoshi;H. Kubo;K. Nishiyama;M. Takiguchi-M.
膀胱癌におけるCOLIA2遺伝子プロモーター領域のメチル化の検討
膀胱癌COLIA2基因启动子区甲基化检测
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    森 勝久;ほか
  • 通讯作者:
    ほか
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NAKAGAWA Masayuki其他文献

NAKAGAWA Masayuki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NAKAGAWA Masayuki', 18)}}的其他基金

Elucidating anticancer drug resistance in urothelial carcinoma by multi-faceted approach
通过多方面的方法阐明尿路上皮癌的抗癌药物耐药性
  • 批准号:
    19K09715
  • 财政年份:
    2019
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Verification of Time Consistency Conditions for Pre-Disaster Prevention Measures and Post-Disaster Relief and Reconstruction Projects
灾前预防措施与灾后救灾重建项目时间一致性条件验证
  • 批准号:
    18H03639
  • 财政年份:
    2018
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Exploring molecular network of functional nucleic acid and developing therapeutic innovations in drug-resistant renal cell carcinoma
探索功能核酸的分子网络并开发耐药肾细胞癌的治疗创新
  • 批准号:
    16H05464
  • 财政年份:
    2016
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Rethinking of City Planning Law by Econimics
城市规划法的经济学反思
  • 批准号:
    21330068
  • 财政年份:
    2009
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Developing new treatment modalities of urothelial carcinoma through regulating microRNA expression
通过调控microRNA表达开发尿路上皮癌新治疗方式
  • 批准号:
    20390427
  • 财政年份:
    2008
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Efficiency Analysis of Economic Planning Policy : Feasibility Studies of Experimental and Empirical Method
经济计划政策的效率分析:实验和实证方法的可行性研究
  • 批准号:
    17203023
  • 财政年份:
    2005
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Establishment of prediction system for the prognosis of patients with bladder cancer
膀胱癌患者预后预测系统的建立
  • 批准号:
    16591603
  • 财政年份:
    2004
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of Low Level Living in Japan Using Audit Study
利用审计研究分析日本的低水平生活
  • 批准号:
    13630054
  • 财政年份:
    2001
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of tumor-associated macrophage in tumor invasion and inhibition of tumor invasion in urothelial cancers
肿瘤相关巨噬细胞在尿路上皮癌肿瘤侵袭和抑制肿瘤侵袭中的作用
  • 批准号:
    12671546
  • 财政年份:
    2000
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Typological Cognitive Study of Grammatical Discrepancy between Kango and Original Chinese
汉语与汉语语法差异的类型学认知研究
  • 批准号:
    11610466
  • 财政年份:
    1999
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
  • 批准号:
    23K08773
  • 财政年份:
    2023
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of treatment to improve cancer cachexia in urothelial cancer
建立改善尿路上皮癌癌症恶病质的治疗方法
  • 批准号:
    23K14361
  • 财政年份:
    2023
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of biomarker predicting the response of immunotherapy for patients with urothelial cancer using urine miRNA
开发利用尿液 miRNA 预测尿路上皮癌患者免疫治疗反应的生物标志物
  • 批准号:
    22K09512
  • 财政年份:
    2022
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Tailor-made immunotherapy strategy for urothelial cancer using immunogram
使用免疫图定制尿路上皮癌免疫治疗策略
  • 批准号:
    21K09368
  • 财政年份:
    2021
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploration of novel combined immunotherapy for urothelial cancer
尿路上皮癌新型联合免疫疗法的探索
  • 批准号:
    21K09412
  • 财政年份:
    2021
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of super-enhancer and master genes involved in treatment resistance of urothelial cancer
鉴定与尿路上皮癌治疗耐药相关的超级增强子和主基因
  • 批准号:
    21K09367
  • 财政年份:
    2021
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
VENTANA PD-L1 (SP142), a complimentary diagnostic immunohistochemistry (IHC) assay to ascertain tumor PD-L1 status for patients with metastatic urothelial cancer considering treatment with atezolizuma
VENTANA PD-L1 (SP142),一种免费的诊断性免疫组织化学 (IHC) 检测,用于确定考虑使用 atezolizuma 治疗的转移性尿路上皮癌患者的肿瘤 PD-L1 状态
  • 批准号:
    10273221
  • 财政年份:
    2020
  • 资助金额:
    $ 2.51万
  • 项目类别:
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
使用恩替司他选择性组蛋白脱乙酰酶抑制可增强尿路上皮癌中免疫检查点抑制的抗肿瘤免疫反应
  • 批准号:
    10378718
  • 财政年份:
    2020
  • 资助金额:
    $ 2.51万
  • 项目类别:
Selective histone deacetylase inhibition with entinostat to enhance the anti-tumor immune response to immune checkpoint inhibition in urothelial cancer
使用恩替司他选择性组蛋白脱乙酰酶抑制可增强尿路上皮癌中免疫检查点抑制的抗肿瘤免疫反应
  • 批准号:
    10132271
  • 财政年份:
    2020
  • 资助金额:
    $ 2.51万
  • 项目类别:
Immunotherapy for urothelial cancer focusing on inactive TGFb (LAP) positive immune cells
针对尿路上皮癌的免疫治疗,重点关注无活性 TGFb (LAP) 阳性免疫细胞
  • 批准号:
    19K16797
  • 财政年份:
    2019
  • 资助金额:
    $ 2.51万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了